Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Insight Molecular Diagnostics (IMDX) Change in Account Payables (2016 - 2020)

Insight Molecular Diagnostics' Change in Account Payables history spans 1 years, with the latest figure at -$6000.0 for Q1 2020.

On a quarterly basis, Change in Account Payables changed N/A to -$6000.0 in Q1 2020 year-over-year; TTM through Dec 2020 was -$6000.0, a N/A change, with the full-year FY2020 number at -$6000.0, up 99.71% from a year prior.
Change in Account Payables hit -$6000.0 in Q1 2020 for Insight Molecular Diagnostics.
Over the last five years, Change in Account Payables for IMDX hit a ceiling of -$6000.0 in Q1 2020 and a floor of -$6000.0 in Q1 2020.